Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Medulloblastoma 3Brain Neoplasms 2Teratoma 1Neuroectodermal Tumors, Primitive 1Meningeal Carcinomatosis 1Lung Neoplasms 1Infratentorial Neoplasms 1Glioma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 10Temozolomide 8Radiotherapy 6Magnetic Resonance Spectroscopy 6Cisplatin 6Filgrastim 5Etoposide 5Carboplatin 5Vincristine 4sargramostim 3Thiotepa 3Melphalan 3Carmustine 3Automobiles 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3fludarabine 2antineoplaston AS 2-1 2antineoplaston A10 2aldesleukin 2Thalidomide 2Paclitaxel 2Irinotecan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Gadolinium DTPA 2Eflornithine 2Donepezil 2Biopsy 2Bevacizumab 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Craniospinal Irradiation × CNS × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡